Gemcitabine + nab paclitaxel

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pancreas Adenocarcinoma

Conditions

Pancreas Adenocarcinoma

Trial Timeline

May 10, 2018 → Oct 16, 2024

NCT ID

NCT03377491

About Gemcitabine + nab paclitaxel

Gemcitabine + nab paclitaxel is a phase 3 stage product being developed by Novocure for Pancreas Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03377491. Target conditions include Pancreas Adenocarcinoma.

What happened to similar drugs?

1 of 4 similar drugs in Pancreas Adenocarcinoma were approved

Approved (1) Terminated (0) Active (3)

✅DaclizumabRocheApproved

🔄Alemtuzumab + Rabbit Anti-Human Thymocyte GlobulinAstellas PharmaPhase 3

🔄Enteric-coated mycophenolate sodium (EC-MPS)NovartisPhase 3

🔄Irinotecan Liposomal Injection + Oxaliplatin + 5Fluorouracil + Leucovorin + Nab-paclitaxel + GemcitabineIpsenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07319910	Pre-clinical	Active	—	—	Locally Advanced Pancreatic Adenocarcinoma
NCT03377491	Phase 3	Completed	May 10, 2018	Oct 16, 2024	Pancreas Adenocarcinoma

Competing Products

20 competing products in Pancreas Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
pemetrexed	Eli Lilly	Phase 2	27
Alemtuzumab + Rabbit Anti-Human Thymocyte Globulin	Astellas Pharma	Phase 3	40
Romidepsin + Azacitidine + nab-Paclitaxel + Gemcitabine + Durvalumab + Lenalidomide capsule	AstraZeneca	Phase 1/2	32
Durvalumab	AstraZeneca	Phase 2	27
MK-2206	Merck	Phase 2	35
Pembrolizumab + DEBIO1143	Merck	Phase 1	29
dovitinib lactate + gemcitabine hydrochloride + capecitabine	Novartis	Phase 1	29
AUY922	Novartis	Phase 2	27
dovitinib lactate + gemcitabine hydrochloride + paclitaxel albumin-stabilized nanoparticle formulation	Novartis	Phase 1	21
FOLFIRINOX + Oxaliplatin + Leucovorin + Irinotecan + 5-Fluorouracil (5-FU) + NIS793 + Capecitabine	Novartis	Phase 1	21
Enteric-coated mycophenolate sodium (EC-MPS)	Novartis	Phase 3	40
Daclizumab	Roche	Approved	43
Gemcitabine + panitumumab	Amgen	Phase 2	27
PF-03084014 + Gemcitabine + Nab-paclitaxel + PF-03084014 + Gemcitabine + Nab-paclitaxel + Gemcitabine + Nab-paclitaxel	Pfizer	Phase 2	27
CRS-207 + CRS-207 + nivolumab + GVAX + CY	Bristol Myers Squibb	Phase 2	35
Belatacept + methylprednisolone + Anti-thymocyte Globulin (Rabbit) + Tacrolimus + Mycophenolate mofetil	Bristol Myers Squibb	Phase 2	27
AK154 + Cadonilimab + Ivonescimab (SMT112 or AK112) Injection + mFOLFORINOX	Akeso	Phase 1	36
Vemurafenib + Sorafenib	Bayer	Phase 2	36
sorafenib tosylate + everolimus	Bayer	Phase 1	26
Pemigatinib 4.5 MG	Incyte	Phase 2	24